Clay Siegall has a Ph.D in Genetics from George Washington University as well as B.S in Zoology from the University of Maryland. He is an accomplished entrepreneur and scientist. He has worked and been in the biotechnology industry for many years therefore he has so much experience. Furthermore, he has scooped an award for being the 2013 Alumnus of the year for computer, Natural sciences and Math from the University of Maryland. Seattle Genetic is a company he co-founded in the year 1998. Apparently he is the CEO and President as well as the chairman of the board of members at the organization.
Biotechnology from the word technology is all about the creation of technology in the world of science. For further information it is the use of various microorganisms to perform specific engineering measures so as to produce artificial hormones and drugs. The company; Seattle Genetic aims for cancer patients because it is a biotechnology. The end goal of the company is to produce the finest antibody drug conjugates (ADC). It is with the best interest of Clay Siegall and his team to ensure that they work hard to help the patients with cancer to get the treatment they deserve. Adcetric is the very first product of the company and so far it is all over 60 countries around the globe.
Clay Siegall has seen the company’s financial rate increase due to the good work they keep doing. His experience and positive energy have placed more than 20 ADCs of the company’s knowledge in various clinical growths. The financial status has over the years reached $330 million in the private and public area. More than 15,000 patients diagnosed with Lymphoma all over the world have been treated with Adcetris.
SGN-CD19A in non-Hodgkin lymphoma and SGN-CD33A in acute myeloid leukemia are other initiatives of Seattle Genetic that are to be used in clinical databases. Clay Siegall is so far impressed with the positive results of the treatments. He and the company believe that there will be better treating therapies in future to boost the lives of the cancer patients. To improve the therapies, Clay Siegall and the company have associated with other companies dealing with cancer treatment.